Ekso Bionics (NASDAQ:EKSO) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note issued to investors on Thursday. The firm set a “hold” rating on the stock.

Several other research firms also recently issued reports on EKSO. HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Ekso Bionics in a report on Tuesday, January 14th. Lake Street Capital dropped their target price on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday, October 29th.

Ekso Bionics Stock Down 7.0 %

Shares of EKSO stock opened at $0.54 on Thursday. The stock’s fifty day moving average price is $0.66 and its 200 day moving average price is $0.91. Ekso Bionics has a 1-year low of $0.50 and a 1-year high of $2.35. The company has a market cap of $11.84 million, a price-to-earnings ratio of -0.83 and a beta of 1.47. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.